October 17, 2025

To, **BSE Limited**, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	To, Listing Department, **National Stock Exchange of India Ltd**., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol**:** CAMLINFINE || Series: EQ

Sub: **Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") – Corrigendum to the Postal Ballot Notice**

Dear Sir/Madam,

The Company has issued the Postal Ballot Notice dated September 29, 2025, along with the explanatory statement, seeking approval of the members of the Company, by way of remote e-voting process ("**e-voting**") for the issuance of equity shares of the Company on a preferential basis pursuant to a share swap arrangement.

Pursuant to the requirements of Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the Company had filed applications for obtaining in-principle approval of the BSE Limited ("**BSE**") and the National Stock Exchange of India Limited ("**NSE**" and collectively with BSE, the "**Stock Exchanges**") for the proposed preferential issue of equity shares ("**Preferential Issue**") as detailed in the Notice along with the explanatory statement thereto.

NSE vide its letter dated October 6, 2025 and BSE vide their remarks provided on the BSE listing portal on October 15, 2025, has asked the Company to provide certain clarifications/ information in respect of the Preferential Issue, by way of a corrigendum to the Notice.

Accordingly, pursuant to Regulation 30 of the SEBI LODR, we are enclosing this corrigendum ("**Corrigendum**") in continuation to the Notice together with the explanatory statement thereof and this Corrigendum shall be deemed to be an integral part of the Notice.

The Corrigendum to the Postal Ballot Notice is also available on the Company's website at www.camlinfs.com.

Request you to please take the same on your records.

Thanking you,
Yours faithfully,
For Camlin Fine Sciences Limited
Rahul Sawale
Digitally signed by Rahul Sawale
Date: 2025.10.17 21:53:54 +05'30'
Rahul Sawale
Company Secretary & VP Legal
Encl.: a/a.

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED

Regd. Office: In G.S. Point, Floor 2 to 5, CST Road, Kalina, Opp. University Campus, Santacruz (East), Mumbai – 400 098

E-mail: secretarial@camlinfs.com • **Website:** www.camlinfs.com • **Tel:** 022-6700 1000 • **Fax:** 022-2832 4404

CORRIGENDUM TO THE POSTAL BALLOT NOTICE

Corrigendum to the Postal Ballot Notice dated September 29, 2025 ("Notice") sent to the Members of Camlin Fine Sciences Limited to cast their votes electronically.

Camlin Fine Sciences Limited ("**Company**") has issued the Notice, pursuant to Section 110 of the Companies Act, 2013 ("**Act**"), Rule 22 of the Companies (Management and Administration) Rules, 2014 ("**Rules**") and other applicable provisions of the Act and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), Secretarial Standard on General Meetings ("**SS-2**") issued by the Institute of Company Secretaries of India and other applicable laws, rules, regulations and circulars issued by Ministry of Corporate Affairs (including any statutory modification or re-enactment thereof for the time being in force and as amended from time to time).

Pursuant to the requirements of Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the Company had filed applications for obtaining in-principle approval of the BSE Limited ("**BSE**") and the National Stock Exchange of India Limited ("**NSE**" and collectively with BSE, the "**Stock Exchanges**") for the proposed preferential issue of equity shares ("**Preferential Issue**") as detailed in the Notice along with the explanatory statement thereto.

NSE *vide* its letter dated October 6, 2025 and BSE *vide* the BSE listing portal on October 15, 2025, has asked the Company to provide certain clarifications/ information in respect of the Preferential Issue, by way of a corrigendum to the Notice.

Accordingly, this corrigendum ("**Corrigendum**") is being issued in continuation to the Notice together with the explanatory statement thereof and this Corrigendum shall be deemed to be an integral part of the Notice. Pursuant to this Corrigendum, the members of the Company are hereby informed and requested to note the following:

For better clarity and understanding:

1. **The introduction of the explanatory statement to the Notice shall be replace and read in the manner set out below:**

   The following Statement sets out all material facts relating to the Special Business mentioned in the Notice:

   Item No. 1: Issuance of Equity Shares of Camlin Fine Science Limited ("Company") on a preferential basis pursuant to a share swap arrangement.

   Vinpai was incorporated and founded in 2011 by Cyrille Damany and Philippe Le Ray. Vinpai's registered office is at 6 Parc d'Activités de la Fouée, FR-56130 Saint-Dolay, France. Vinpai is an ingredien'tech company specializing in the design, manufacture and marketing of algae, plants, mineral and fibre-based functional ingredients offering manufacturers natural alternatives to chemical additives. Positioned in the most promising market segments, Vinpai now supports manufacturers in the food industry, its historical market, cosmetics and nutraceuticals, thanks to cross-technology know-how, enabling them to increase the nutritional qualities of their finished products. The combination and association of ingredients and food additives allows manufacturers to accelerate their development, optimize their production costs and generate profitability. Operating from two sites, in Saint-Dolay (Morbihan) and near the port of Saint-Nazaire, Vinpai has developed more than 3,500 formulas and now has 43 employees. In 2024, the Company generated revenues of €9.2 million, including more than 70% of which from exports, and generates sales in more than 36 countries. Vinpai is listed on the Euronext Growth Paris since its successful IPO on July 19, 2023 (ISIN: FR001400AXT1; ticker: ALVIN).

   The synergy between Vinpai's R & D capabilities, its product range and Company's expertise promises to enrich the Company's product offerings, fostering innovation and bolstering competitiveness in the global market. This strategic move leads Company into a newer product range in the natural space, opens up exciting markets and also leverages the expansion of its revenues and margins.

   *On February 24, 2025, the Company and certain significant shareholders of Vinpai ("*Investors*"), the allottees of this preferential issue, have entered into the SPA for acquisition* 27,23,316 ordinary shares constituting *of a majority stake in Vinpai representing approximately 78.68% of Vinpai's outstanding share capital. The consideration to be paid by the Company to the Investors for each Investors' share in Vinpai shall be equal to € 3.60.*

   Concomitantly with the signing of the SPA, the Company has granted a financing to Vinpai for an amount of €3.3 million through the subscription of listed secured convertible bonds. Subject to and simultaneously with the acquisition of aforesaid shares of Vinpai from the Investors, the convertible bonds will be converted into ordinary shares of Vinpai.

The present preferential issue is being undertaken as consideration towards the acquisition of ordinary shares of Vinpai, a French société anonyme from the Investors by the Company pursuant to a share swap arrangement, in accordance with the terms of the SPA.

Name of Shareholders	No. of Shares held in Vinpai	Percentage	Consideration @ € 3.60 per Share	Consideration @ INR (Exch. Rate € 1 = INR 103.74)	No. of Swap Shares of CFSL (Floor price = INR 247.69)	No. of Shares Round Down	Consideration (Floor price = INR 247.69)	Cash Difference (INR)	Cash Difference (Euro)
Cyrille Damany	8,29,136	23.95%	29,84,890	30,96,52,447	12,50,161	12,50,161	30,96,52,378	69	0.67
Philippe Le Ray	5,15,000	14.88%	18,54,000	19,23,33,960	7,76,511	7,76,510	19,23,33,762	198	1.91
Alexandre Moranville	2,30,313	6.66%	8,29,127	8,60,13,614	3,47,263	3,47,263	8,60,13,572	42	0.40
Chris Project	8,43,524	24.37%	30,36,686	31,50,25,847	12,71,855	12,71,855	31,50,25,765	82	0.79
Saffelberg Investments	3,05,343	8.82%	10,99,235	11,40,34,618	4,60,392	4,60,392	11,40,34,494	124	1.19
Total	**27,23,316**	**78.68%**	**€ 98,03,938**	**₹ 1,01,70,60,487**	**41,06,183**	**41,06,181**	**₹ 1,01,70,59,972**	**₹ 515**	**€ 4.96**

Note: The cash difference on account of rounding off and the same has been ignored by the Company while calculating the final number of shares which are proposed to be issued and allotted.

The Investors have confirmed their eligibility in terms of Regulation 159 of the SEBI ICDR Regulations, to subscribe to the fully paid-up Equity Shares of the Company, to be issued pursuant to the Preferential Issue.

In accordance with Sections 23(1)(b), 42 and 62(1)(c) and other applicable provisions, if any, of the Act and the rules made thereunder and in accordance with the SEBI ICDR Regulations and the SEBI Listing Regulations, as amended from time to time, approval of the Members of the Company by way of special resolution is required to issue securities by way of a preferential issue on a private placement basis.

The proposed preferential issue is for consideration other than cash and hence the disclosures information as per guidance note "Guidance note on inclusion of "Object of the issue" in case of Preferential issues (in the Explanatory statement to the notice to the shareholders) and in Qualified Institutions Placement ("QIP") (in the preliminary and final placement document) under Chapter V and VI of SEBI (ICDR) Regulations, 2018, respectively" dated 13.12.2022 issued by BSE are not applicable.

Accordingly, in terms of the Act and the SEBI ICDR Regulations, consent of the Members is being sought for the Preferential Issue in the manner detailed hereafter."

2. **Point i of the explanatory statement of the Notice shall be replaced and read in the manner set out below:**

i) Objects of the Issue

Vinpai is an ingredien'tech specializing in the design, manufacture and marketing of functional ingredients based on algae, plants, minerals, and fibers, offering manufacturers natural alternatives to chemical additives. Positioned in the most promising market segments, Vinpai provides support to food, cosmetics and nutraceutical manufacturers, thanks to its cross-technology know-how, enabling them to upgrade the nutritional qualities of their end products. The combination of mixing of ingredients and food additives enables manufacturers to accelerate their development, optimize their production costs and generate profitability. Further Vinpai's subsidiary, Based Algae and Plants, serves as its main sales and vehicle company. Vinpai operates across Europe, North Africa, West Africa, and Southeast Asia. The company aims to expand into the feed market by leveraging its technology in production and marketing, pursuing new revenue streams. Vinpai's technology is expected to enhance product quality, increase yields, and diversify offerings. This acquisition will support technological advancement, improved customer satisfaction, and business growth to the Company.

In view of the aforementioned objective, on February 24, 2025, the Company and certain significant shareholders of Vinpai ("Investors"), the allottees of this preferential issue, have entered into the SPA for acquisition of a majority stake in Vinpai representing approximately 78.68% of Vinpai's outstanding share capital.

The present preferential issue is being undertaken as consideration towards the acquisition of ordinary shares of Vinpai, a French société anonyme from the Investors by the Company pursuant to a share swap arrangement, in accordance with the terms of the SPA.

Accordingly, the Company intends to issue and allot a maximum of 41,06,181 Equity Shares, as consideration towards the acquisition of ordinary shares of Vinpai, a French société anonyme ("Swap Shares"*), determined in accordance with the terms of the SPA, pursuant to a share swap arrangement, by way of a preferential issue on a private placement basis to the Investors.*

The requirement of appointing a monitoring agency per the Regulation 162A of the SEBI ICDR Regulations is not applicable since the present preferential issue include issuance of shares for a consideration other than cash (i.e., in the nature of swap of equity shares) and the Company will not be receiving any proceeds from the issue.

3. **Point vii of the explanatory statement of the Notice shall be replaced and read in the manner set out below:**

vii) Shareholding pattern of the issuer before and after preferential issue

The shareholding pattern of the Company before and after the Preferential Issue (on a fully-diluted basis) is as follows:

S. No.	Category of shareholder(s)	Pre – Issue		Post – Issue *(on a fully diluted basis)*	
		(based on BENPOS dated September 26, 2025)			
		No. of shares held	% of share holding	No. of shares held	% of share holding
A	Promoters & promoter group holding				
1	Indian				
a)	Individual	1,98,67,080	10.57	1,98,67,080	10.14
b)	Bodies Corporate	94,23,300	5.01	94,23,300	4.81
c)	Others	-	-	-	
	Sub-Total (A)(1)	2,92,90,380	15.58	2,92,90,380	14.95
2	Foreign	6,29,73,673	33.50	6,29,73,673	32.13
	Sub- Total (A)(2)	6,29,73,673	33.50	6,29,73,673	32.13
	Total Promoters & Promoter Group Holding (A)	**9,22,64,053**	**49.08**	**9,22,64,053**	**47.08**
B	Non-Promoters Holding				
1	Institutional Investors	1,42,45,868	7.58	1,42,45,868	7.27
	Sub-Total (B)(1)	**1,42,45,868**	**7.58**	**1,42,45,868**	**7.27**
2	Non-Institutions				
	Private corporate bodies	1,35,19,961	7.19	1,35,19,961	6.90
	Directors and relatives	45,18,574	2.40	83,13,750	4.24
	Indian public	5,57,52,157	29.66	5,57,52,157	28.45
	Others (including NRIs)*	76,79,819	4.09	1,18,81,000	6.06
	Sub-Total (B)(2)	8,14,70,511	43.34	8,94,66,868	45.65
	Total Public Shareholding (B)	**9,57,16,379**	**50.92**	**10,37,12,736**	**52.92**
	Total (A)+(B)	**18,79,80,432**	**100.00**	**19,59,76,789**	**100.00**

* Includes Preferential Issue made to the Investors.

4. **Point xii of the explanatory statement of the Notice shall be replaced and read in the manner set out below:**

xii) The percentage of the post-preferential issue capital that may be held by the Investors and change in control, if any, in the Company consequent to the Preferential Issue

Sr. No.	*Name of the proposed allottee/Investor*	*Pre-preferential issue shareholding*		*Post-preferential issue shareholding (on a fully diluted basis)*	
		No of securities	*% of shareholding*	*No of securities*	*% of shareholding*
	Public Category				
1	*Cyrille Damany*	0	0.00	12,50,161	0.64
2	*Philippe Le Ray*	0	0.00	7,76,510	0.40
3	*Alexande de Selliers de Moranville*	0	0.00	3,47,263	0.18
4	*Chris Project*	0	0.00	12,71,855	0.65
5	*Saffelberg Investments SA*	0	0.00	4,60,392	0.23
	Total	***0***	***0.00***	***41,06,181***	***2.10***

There will be no change in the composition of the Board nor any change in the control of the Company consequent to the proposed Preferential Issue.

5. **Point xvi of the explanatory statement of the Notice shall be replaced and read in the manner set out below:**

xvi) Valuation and Justification for the allotment proposed to be made for consideration other than cash

The Company intends to issue and allot a maximum of 41,06,181 Equity Shares, as consideration towards the acquisition of ordinary shares of Vinpai, a French société anonyme, determined in accordance with the terms of the SPA, pursuant to a share swap arrangement, by way of a preferential issue on a private placement basis.

The Board has approved the issue price of ₹ 247.69/- for issue of fully paid-up Equity Shares, by way of Preferential Issue as per Chapter V of SEBI ICDR Regulations.

While the proposed Preferential Issue is not expected to result in a change of control or the allotment of more than 5% of the post-issue fully diluted share capital of the Company to any allottee or group of allottees acting in concert, the Company is required to obtain a valuation report from an independent registered valuer for price determination, pursuant to Regulation 163(3) of the SEBI ICDR Regulations. The following are the details of the registered valuer who has issued the report in this regard.

Name of the valuer: Sundae Capital Advisors Private Limited - Category I Merchant Banker registered with SEBI IBBI Registered Valuer (SFA)

Address: 1177, 11th Floor, VEGAS, Plot No. 6 Sector 14 (North), Dwarka City Centre New Delhi - 110 075

A valuation report dated September 29, 2025 by Sundae Capital Advisors Pvt. Ltd., an independent registered valuer as per Chapter V of the SEBI ICDR Regulations, is available on the website of the Company at the following web link: https://www.camlinfs.com/investor-relations/home/corporate_announcements.

None of the Promoters/Promoter Group, Directors / Key Managerial Personnel of the Company / relatives of Directors and Key Managerial Personnel are, in any way, concerned or interested, financially or otherwise, in the special resolution mentioned at Item No. 1 of the Notice.

All other contents of the Notice together with the explanatory statement thereof, save and except as modified or supplemented by the Corrigendum, shall remain unchanged. Capitalized terms used but not defined herein shall have the same meaning ascribed to them in the Notice and the explanatory statement thereof.

This Corrigendum shall form an integral part of the Notice together with the explanatory statement thereof, which has already been circulated to the members of the Company on September 29, 2025, and on and from the date hereof, the Notice together with the explanatory statement thereto shall always be read in conjunction with this Corrigendum. Accordingly, all concerned shareholders, Stock Exchanges, depositories, registrar and share transfer agent, agencies appointed for e-voting, other authorities, regulators, and all other concerned persons are requested to take note of the above changes.

As e-voting has already been commenced, the members are hereby informed that the Company offers an opportunity for those who have already cast their vote on the proposed resolution to update their response based on the additional information provided in this corrigendum. Members wishing to amend their vote are requested to submit their assent (FOR) or dissent (AGAINST) to the Scrutinizer appointed by the Company via email ID **jhr@jhrasso.com** no later than 5:00 p.m. IST on Wednesday, October 29, 2025. Submissions received after this deadline will not be considered, and it will be deemed that no response has been received from the Member.

This Corrigendum is available on the website of the Company at www.camlinfs.com, the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com respectively, and is also available on the website of NSDL at https://www.evoting.nsdl.com/**.**

By Order of the Board
For **Camlin Fine Sciences Limited**
Rahul Sawale
Company Secretary
& VP – Legal

Regd. Office:
Camlin Fine Sciences Limited
CIN: L74100MH1993PLC075361
In G.S. Point, Floor 2 to 5, CST Road,
Kalina, Opp. University Campus,
Santacruz (East), Mumbai - 400 098
Website: www.camlinfs.com
E-mail: secretarial@camlinfs.com
Tel.: +91 22 6700 1000
Fax: +91 22 2832 4404

Place: Mumbai
Date : October 17, 2025